Does Proprietary Data Hinder Research?

Does Proprietary Data Hinder Research?

A widely-discussed article at Newsweek about the ‘data problem in medicine’ sheds light on the fact that doctors don’t have access to data about the very medicines the prescribe. In fact, of all clinical trials, as many as half are never published, leaving doctors in the dark and patients at risk.

In the perhaps most extreme example, an antiarrhythmic drug called lorcainide was tested in the 1980s, and 9 people of the lorcanide group died vs. just one of the placebo group. This study could have prevented thousands of deaths during the decade, but was, for some reason, never published until the researchers apologized for the fact in 1993.

This is, in part, a problem of the community: journals are more likely to publish positive results as they can, well, sell more copies this way. On the other hand, manufacture of pharmaceuticals is a multi-billion dollar industry so money tends to slip into the equation when it shouldn’t.

For there is a real commercial boon in not sharing all trial data: on the surface, pharmaceutical companies can suffer greatly from the competitors if the published studies reveal the way the drugs work. On another level, there’s, also the incentive to push a drug that has swallowed a lot of money for fear of not making up for the investment. This, of course, extends beyond the pharmaceutical industry.

Proprietary data in economics

An intriguing article at Quartz acknowledges that more and more studies are based on proprietary data. In fact, from the studies published in the American Economic Review, a very prestigious economic journal, the number that use proprietary (either Government or private) data has risen from 8% in 2006 to 46% in 2014. That is, researchers have asked either the government or private companies for data, and more and more virtually unreplicable studies are being published.

Here’s the rub. Companies like Amazon, Facebook and Google, which have hoarded petabytes upon petabytes of data, have a) no real incentive to do anything noncommercial with the data; b) a negative incentive to share the data; c) but even if they do, they are likely to share it with those who would paint a rosy picture about them. A recent study on proprietary data states just that: “To obtain those data, academic economists have to develop a reputation to treat their sources nicely.” And treat them nicely they will, because such data sets are too unique and (one might imagine) too interesting to pass by.


Proprietary data, then, in some fields can be seen to be plainly bad, like in the cases of drug trials. In other fields, the effect cannot be measured, but there’s a very real danger that we’ll have a publication bias towards praising the company that released the data set to the researcher. It’s inevitably a trade-off, but for now it’s the only way scientists can access that data.

By Lauris Veips

Gilad David Maayan
Network Security in the Public Cloud What is Network Security? Network security is a strategic approach to securing an organization’s resources and data across the corporate network. It helps protect organizations of all sizes, industries, ...
Gilad David Maayan
What Is Cloud Deployment? Cloud deployment is the process of deploying and managing applications, services, and infrastructure in a cloud computing environment. Cloud deployment provides scalability, reliability and accessibility over the internet, and it allows ...
Maxim Melamedov
Trouble is Brewing Cloud Paradise - 2023 Will Determine Company's Long-Term Plans for Cloud Use The relationship between developers and the cloud was practically love at first sight. For years, migration to the cloud in ...
Martin Mendelsohn
The Colonial Pipeline Dilemma The Colonial Pipeline is one of a number of essential energy and infrastructure assets that have been recently targeted by the global ransomware group DarkSide, and other aspiring non-state actors, with ...
John Peluso
Save Your Organization on Cloud Costs Organizations of all sizes are currently navigating their plans to avoid the recent surge in cyber-attacks and data breaches and preparing for unforeseen setbacks. Building a sensible backup and ...
Gary Bernstein
Common DevOps Misconceptions 86% of businesses say it’s important for their company to develop and produce new software fast to win market share and beat the competition, Harvard Business Review reveals. Yet, just 10% of businesses ...
Frank Suglia
Migrating Microsoft Office 2013 As of April 11, 2023, Microsoft will stop supporting Office 2013. The decision to end support for Office 2013 should come as no surprise. Over the past several years, Microsoft has ...
Tosin Vaithilingam
Divestitures: What to consider during the migration process "Divestitures require careful planning and execution, but they can create tremendous opportunities for companies to transform their businesses and unlock new growth potential." - Ginni Rometty, former ...